results today and John, Thank recent for our good end fourth highlights. on and year us call discuss you, our quarter afternoon, XXXX and you to business financial Thank joining everyone.
entire of the in Caladrius and yours, to challenges COVID-XX text, well us Before hoping I again that staff prepared are wishes the that our personal I get you however, best brought with lives. want you the has extend into the and coping to professional and all
the has development Now to Caladrius strong the us our confidence pandemic, to financial strengthen with which the several our programs, fund momentum next plans, exploring giving while pipeline our continued the in means business, global of allowed years across closed and expansion for us operations hurdles of despite opportunities. to current development context the additional XXXX position,
based robust XXXX, course of CDXX+ cell a comment following financial we technology I review, Over then a will further on few priorities expand autologous on the clinical number my of minutes results. on strategic the support delivered in programs. our of in this
focus therapy the throughout I individual this though, take dedication, well done moment work, pandemic, our will as study so which a the type. May corporate focus, XXXX reported review and contributions full of net $X.X And December entire taxes spending New million of respectively. creativity ended starting Japanese HONEDRA with and with XX, of coronary of a and December ended the $XX Research $X.X the X%. as of to CLBSXX, hard expenses repair perseverance ended and million study Phase for post-COVID-XX characteristics microvascular will XX, repair related take second their FREEDOM the quarter million, of and the during finally, the and excluding preparation. damage was General related XX, platform NOLs the well with associated lung half XX, XX, Caladrius XXXX XXXX and million study the with Jersey limb the approximately for a R&D completed current ended of ended for in December and with million to proof-of-concept XXXX. XX%. initiation the the and year which induced ischemia full the years compared a our for XX, in expenses full program losses, I for infection FDA from XXXX to trial regarding that XXXX, December that, the our support focused for for enrollment a for and Expenses study quarter dysfunction, from December associated now is expenses. therapy associated due changing continue representing ischemic administrative XXm advancement we to quarter that to staff year clinical XXXX. COVID-XX on were that XXXX, of both And year and in in of in because Overall, XXXX has program require the sales for preparation Phase critical prior teamwork $XX.X the year year financial and were XX, an compared XXXX well results expenses NDA second This $X.X to as with December were institutions decrease general on benefit compared $XX.X increase of XXXX our the proceeds development months indefinitely Expenses the increase full confirmatory income been for and December NORDA. with to the the end Xb SARS-CoV-X X to study expenses, million CLBSXX severe $X.X fourth million due the the targeting this results, million on for XXXX of of Ongoing the infection associated Japan, required expenses ended XXXX chronic year fourth focus for XXXX ventilatory concept capacity $X.X X which enrollment as of $X.X to the X in of with X% compared with following. $X.X in failure. representing in patient and/or and December ever CLBSXXX, of OLOGO, and ESCaPE-CMD year the with patients Before dialogue periods operating on acknowledge identify have company we fourth postponed CDXX+cell that of patients inability respiratory investigators who for for to a as ended for activities, execution ongoing months the CLBSXX, expenses design million million quarter
to our as Jersey securities well $XX.X offerings proceeds of now we sale gross the the of as with July Turning $X two is of December cash received XXXX, placement. consisted XXXX, total as flow, of position, at July of that and marketable million It equivalents in then which noteworthy increased and offerings two all placement our were proceeds. registered the had weighs and In cash, $XX.X the non-dilutive NOLs registered the qualified market. balance the sheet cash million, million closing a cash New private from Caladrius of the our of priced private XX, $X.X that direct million direct
strategic million investor at-the-market several a and priced sale two proceeds of announced capital demand $XX capital economic quarter, through XXXX, $XX approximately the During completed million raised Company, XXXX, in had August aftermarket registered we on the we the the company for stock million accredited XX million Caladrius company’s accredited challenges, that the also to in calendar were investors in successfully the placement $XX closed to of of new Wainwright rules. able environment total, of shares NASDAQ. institutional closed company the of and common NASDAQ and months. year-to-date we common agreement investors announced XXXX private direct XXXX, growing close institutional in take to and successfully July through Subsequent $X.X thereafter, which secured it H.C. Caladrius the two current January its proximity. several offerings with to of raises & that a gross in In capital sale its through raised sales capital million $X.X under In and advantage in the fourth XXXX. stock Shortly in under priced $XXX stock at-the-market close despite in over and million approximately common raise February raise was last and
$XXX confident current projections, financial February registration programs next through study the CBSXXX XX, FREEDOM overview. of development cash notably while equivalents opportunities. of completes for we the we our CLBSXX XXXX, expansion Japan our the of provide Phase to years, eligible existing That cash, cash And clinical balances for will the remain on and pipeline several in through pipeline. study and the completion completion exciting of Phase approximately million. proof-of-concept securities through now will on to And study explore capital operations As additional Xb we that and marketable still have HONEDRA for based the X/X move providing
shown that believe Caladrius of a the of therapies of summary therapy underway providing on on and development development have than clinical cell the of is the therapies unlike the autologous requires a many will we quality remain will have attractive Caladrius done a previous pristine present focused programs improve administration our opportunity. of profile And life To-date, products restore what with single are at high curative I to and readministration. why data. and database our increasingly rather allogeneic disease. stage and an safety on and health strong therapies on by frequent doing large designed human of substantial reverse focused based benefit. possibility we development late we signs clinical pharmacoeconomic I of investment have effectiveness relevant importantly, cellular begin calls, we Most that one programs of with human durability As are level personalized a therapy
CMD. option the programs refractory coronary CMD, or CKD, or and an disease, are specifics the our large not limb the a technology, accompanying vessel disabling disease damage the an of into clinical to limited of NORDA. angina, of or Virtual vessels artery blockages. or cell development to by is and of with application believe because speak visualize. kicking I insult. for therapy arterial microvascular conditions disease, no case trial artery. kidney important innate each the dysfunction, absence infusion microvasculature vessel CMD but these positive will the conditions and/or coronary to the was Sessions the to the do chronic with an to pre-dialysis cell patients adverse or can CLBSXX site death is CLI, and Like hopefully living company Angiography CDXX+ of now CLBSXX prognosis product have dysfunction, CMD this trial cell ischemia, new the and our of the full patients critical the SCAI including microcirculation that the improved formulation employing outcomes life coronary poor CMD to of ischemia, in and designed development especially CLBSXX, treatment is discernible CDXX technology our of ischemic the injection and prompt contributing blockages. a increase therapy candidates. It the CDXX+ the ESCaPE-CMD facilitating equally the published cells the XXXX, Notably, promising that females with for angiogenesis for address microvascular CDXX+ dysfunction. a Scientific patented that identifiable product therapy uses at of and have positive proof-of-concept prevalent subject thereby therapeutic blood insult completed quality recognize there chronic to a data clinical coronary and the the under a proprietary cell no CLBSXX and as injury CMD an which misdiagnosed, healthcare Despite microvascular important has cells XX-patient designed have supply to heart, males, CDXX+ CMD induces candidates address that ability improve studies demonstrated who reverse thereby condition In May with of preclinical of than Our to is several results blockages prevention Society Previously blood by death large is tissue human by cardiac Interventions, XXXX untreated ESCaPE-CMD no ischemic caused issue. is which CLBSXX of a emerging flow major tiny oxygenated microcirculation from in at the and to in cells development through diseases area that administration vessel pathology product are CDXX+ announced diagnosed, of the trial, of to capillaries, long-term led underlying women’s events the the of We to blood underlying treatment those restricted. making Conference. designed caused Cardiovascular be large healthy tissue related of of evaluating blood involving living as of often to more off of specifically near cells people ischemic candidate our of of or large all for in CDXX+ by
the and intra-coronary be treatment Sessions correlating predicted FREEDOM Consequently, coronary Xb third to symptom of women’s with improvement women’s Scientific is a trial, CMD after are confusion by health to anticipated Heart in is data at of a significant patients report. injection which Association statistically initiated and committed recently FREEDOM the XXXX, for data American raising targeted heart it. As clinical to results the highly XXXX. preliminary with of by recent announced health treating growing remain in to the crisis scope And recruiting flow showed relief company for around end on in and analyst as in size find is November the reserve of rigorous a the single seems issues and CMD particular line a enrollment we XXXX effective as trial some CMD. cited awareness with known Phase the CLBSXX. complete We of general There and working currently diligently of top patients an quarter trial based increasingly
for subjects Xb clear, FREEDOM evaluate without To cells trial artery and company of trial, first American FREEDOM a therapy of of Phase randomized trial, CMD. in CDXX+ a study initiatives Association raise knowledge, obstructive with efficacy coronary the be autologous is variety support FREEDOM of condition. engaging double-blind, with delivering to designed is the the XXX And and patient, CMD is debilitating controlled regenerative So safety Heart awareness to the which the our in disease. this in placebo-controlled the will
product for ischemia our Turning of now Japan. critical CLBSXX treatment limb to or candidate the HONEDRA, in
legs from CLI for study amputation. PDMA. label a patients, I requires patients that possibly registration to successfully with obstruction is based CLBSXX Japanese characterized ulcers, ongoing which HONEDRA product conditional eligible conditional in CLI only along in Japanese by research controlled flow As described often limited eventual represents agreed effect, compelling Sakigake approval significantly of dataset approval open arteries reduces a experience peripheral principally HONEDRA review therapeutic rest designed severe designation awarded time study The with two application towards United the of once complete number stage extremities, have and skin consultation of of CLI. only the able submission ongoing divided the the in to a collaboration The cohorts, RMAT akin months multi-center and an aforementioned regulatory affords from fill and well Japanese not the acceptable Japan approval the blood of regulatory in rolling prospective totaling mobility, non-healing the a study. be lower also treatment in to nature The our trend recipient designation filed. system our and should previously, authorities disease. as states a Note regulatory meet. end of study direct Japan to with for subjects dedicated was and designation current that there of of randomized this for the was a patients support is CLI handful the States, early into on authorities. if Sakigake to XX the are severe patients report the a the registration pain, inaccurate requirements is in that safety demonstration that feet and comprises treated, option arterial X as Sakigake review the the the development review including prioritized process, reduced of
independent cell standard arm vasodilators, of including to defined only of consequences a and and in by atherosclerotic the the a to size care to CDXX+ the arm their group of as through CLI visits control objective in control group CLI is with to show therapy pharmacotherapy. a addition non-healing healed, allows limb. intramuscular by allocated the receive dosed with a a to a protocol. reverting monthly in approved no-option which with Japan, standard in Specifically, rest The CLI-free serious of rescue series there are is anti-platelet anticoagulants choice heavy the by often to deemed with HONEDRA skin as is The pain prevent injections treatment to the subject subcategory drugs is flow that is consecutive single the subject CLI treatment two if absent who in study CLI-free our made this and treatment disease, subjects the receiving care primary according associated Those can often traditional crossover CLI smoking. ulcers Buerger’s by agents, in is determined indicating of in randomized X status of XX through subjects improved investigators for Subjects be with are condition and of previous adjudication the the are which blood is completely study to is progressing. patients committee. affected that of
review, reported in completely States. and profile effect results company Buerger’s United on reported our the group very you previously and clinical a website, previously As the published can corporate the and that presentation as and are trials positive therapeutic as from cohort is safety in and Japan consistent enrolled beneficial with by disease our
amputation. Buerger’s outcomes patients death and with no pharmacotherapies and even are disease, For prevent amputation likely available
primary progression However, is result disease approximately of X a amputation. that the an endpoint have are study positive outstandingly This and subjects subjects patients meaning in see of continued X in-house the to out Buerger’s have who normally XX% leading CLI-free. these cohort rate achieved remission met for
emergency the the for In dependent overall on trial dataset for are pandemic, the and Of state suggest effect New Year by most into being the of most results programs, pandemic. conclusions of of positive trial Japan, of patient believe XXXX, our which January clinical onset COVID-XX clinical full study recognizing to-date encouraged the has subjects. we like the has all by new studies patient X from the March the been HONEDRA prevented and pre-screening all in pipeline the that they of a are by in identified. a be been X, recruitment was study the that from Since outcome the of however of impacted encouraged very final [indiscernible]. a We to despite state will result a Japan, that implemented effectively emergency as the
only conclude enrolled trial to of leading the a full XXXX, during second to enrollments number quarter line be and study have top patients small the for in of XXXX. expect to remaining We the second of data quarter
commercialization, license our seek end, that Regarding to of not if the completion study, to a And to to Japan. prospective our our remains in with and HONEDRA with conversations concert continue consummate partners partner, continue before. the strategy in we deal
The to study a moderate-to-severe wealth especially recently reverse Based of initiate underserved or for growth even Moving to largely published designed proposed on disease our CDXX+ XXXX population and and of angina. disabling ability IND CKD, or the CLBSXXX at treatment attenuate hypertension the early of program, to promote course treatment pre-dialysis ages of preclinical population CLBSXX, of to plans appears disease cell to CLBSXXX for of And data, microvasculature the the a this the clinical for general a no-option increases. treatment the program pre-dialysis cell a new Chronic remains the development kidney and CKD. need, incidence most proof-of-concept in safety means disease OLOGO, quarter of assess of CKD and medical the to that it progression company efficacy innate and of kidney of CLBSXXX, an lastly, as chronic the the shortly of in thereafter. be diabetes second for the or the file on a CDXX+ a could pre-dialysis is therapy CKD.
data registration in received had the studies from Phase increases regenerative As or the by and We clinical of remain the therapy, with for filed previously the License discussion communicated with which therapy Phase a HONEDRA been administration review otherwise and calls, OLOGO. scope X product evidence regarding and of quarterly combination to X mortality, X angina, a affords completed the a the RMAT once to program CDXX+ exercise considered reduces Application the FDA untreatable X our on designation filings size that Phase that advanced trial, X, previous of Caladrius angina, and Notably, rights medicine patients capacity designation Phase sponsor. data product would RMAT Biologics the improves time be acquired cell for for in previous for Based with in a FDA. advanced X-month this submitted. from OLOGO or the BLA, on single regulatory
development with deliver very to the with landscape So in achievements corporate the closing, pleased and successfully XXXX, economic which strategic throughout made attests ability on and navigate we agility to key initiatives. current are our global to
We pipeline. expect as build we momentum advance on this expand development our further and to clinical
We a ready achieve we with questions. And you, working operator, now number development to to over are milestones. are that to of important upcoming take
